Novartis reports positive performance of combination melanoma therapy

Novartis has announced new clinical data that demonstrates the survival benefits associated with a Tafinlar/Mekinist treatment regimen for advanced melanoma.

Results from the phase III COMBI-v study demonstrated a better overall survival result and a progression-free survival benefit for patients with BRAF V600 mutation-positive advanced melanoma when treated first-line with the combination of Tafinlar and Mekinist.

An estimated 45 percent of patients who received the Tafinlar/Mekinist combination therapy were alive after three years of follow-up, compared to 31 percent of those receiving BRAF monotherapy.

This is the second trial to confirm three-year landmark overall survival data for this promising combination.

Dr Alessandro Riva, global head of oncology development and medical affairs at Novartis, said: "These results underscore our commitment to advancing the practice of precision oncology and extending patients' lives through treatment options that target the root cause of their cancer."

Tafinlar/Mekinist is approved for patients with unresectable or metastatic melanoma with a BRAF V600 mutation in the US, EU, Australia, Canada and other countries.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.